The existing conventional treatments for breast cancer, including immune checkpoint blockade, exhibit limited effects in some cancers, particularly triple-negative breast cancer. Epigenetic alterations, specifically DNMT and HDAC alterations, are implicated in breast cancer pathogenesis. We demonstrated that DNMTs and HDACs are overexpressed and positively correlated in breast cancer. The combination of DNMT and HDAC inhibitors has shown synergistic antitumour effects, and our previously designed dual DNMT and HDAC inhibitor (termed DNMT/HDACi) 15a potently inhibits breast cancer cell proliferation, migration, and invasion and induces apoptosis in vitro and in vivo. Mechanistically, 15a induces a viral mimicry response by promoting the expression of endogenous retroviral elements in breast cancer cells, thus increasing the intracellular level of double-stranded RNA to activate the RIG-I–MAVS pathway. This in turn promotes the production of interferons and chemokines and augments the expression of interferon-stimulated genes and PD-L1. The combination of 15a and an anti-PD-L1 antibody had an additive effect in vivo. These findings indicate that this DNMT/HDACi has immunomodulatory functions and enhances the effectiveness of immune checkpoint blockade therapy.
25 February 2021 in Advanced Synthesis & Catalysis
Chiral oxazolidines are pivotal structural motifs commonly found in natural products, medicinally important compounds, and chiral ligands. Among various synthetic strategies, the asymmetric formal (3 + 2) annulation of donor–acceptor (D–A) aziridines with dipolarophiles has emerged as a powerful method for constructing enantioenriched five-membered azaheterocycles with potential bioactivity. Herein, we present a Cu(II)/chiral phosphoric acid (CPA) cooperative catalytic system for the asymmetric intermolecular (3 + 2) cycloaddition of D–A aziridines with aldehydes via C–C bond cleavage. This approach enables the efficient and highly enantioselective synthesis of cis-(2S,5S)-1,3-oxazolidines with excellent atom economy, as well as exceptional chemo-, enantio-, and diastereoselectivities. This novel activation model, distinct from existing catalytic methodologies, serves as a complementary approach that significantly broadens the scope of asymmetric (3 + 2) cycloaddition of D–A aziridines. Moreover, the resulting chiral oxazolidines exhibited significant anti-proliferative activity against various human cancer cell lines, highlighting their potential for further advancement in medicinal chemistry.